BioCopy develops TCR-mimetic bispecific antibodies against cancer, with an R&D site in Emmendingen, Germany. The company has closed a CHF 9 million tranche of its Series A round to fund the preclinical studies needed to file an IND for its lead candidate.
- Announced on
- Round
- Series A
- Amount
- CHF 9 M
- Location
- Basel, canton of Basel-Stadt
- Sector
- Biotech & life sciences
Investors
The investors were not named in the announcement.
Preparing a similar round?
The diagnostic shows you the instruments and investors that fit your stage.
Start the diagnostic